Dean Y. Li

Dean Y. Li is an American physician-scientist and pharmaceutical executive renowned for his research in vascular biology and his leadership in biomedical innovation. His career has spanned academic medicine at the University of Utah, research leadership at Merck & Co., and executive roles in biotechnology. Li's work has significantly advanced the understanding of angiogenesis and inflammatory disease, translating fundamental discoveries into therapeutic strategies.

Early life and education

Dean Y. Li completed his undergraduate studies at the University of Chicago, where he developed a foundation in the biological sciences. He then earned his M.D. and Ph.D. degrees through the prestigious Medical Scientist Training Program at the University of Pennsylvania. His doctoral research, conducted at the University of Pennsylvania School of Medicine, focused on molecular mechanisms underlying cellular signaling. Following this, Li moved to Boston to complete his residency in internal medicine at Brigham and Women's Hospital, a major teaching affiliate of Harvard Medical School.

Career and research

Li began his independent research career at the University of Utah, where he rose to become a professor in the Department of Internal Medicine and an investigator at the Program in Human Molecular Biology and Genetics. His laboratory made seminal discoveries in vascular development, identifying critical pathways like the Notch signaling pathway in artery-vein specification and the role of CCN1 in angiogenesis and inflammation. This work, often published in journals like *Nature* and *Science*, provided new targets for treating cardiovascular disease and cancer. His research bridged basic science and translational medicine, influencing drug discovery efforts at multiple pharmaceutical companies.

Leadership roles

In 2011, Li transitioned to the pharmaceutical industry, joining Merck & Co. as Vice President of Translational Medicine. He later ascended to become President of Merck Research Laboratories, overseeing the company's global drug discovery and development portfolio across therapeutic areas including oncology, vaccines, and cardiovascular research. In 2021, he took on a prominent role in biotechnology as the first President of Verily Life Sciences, an Alphabet company, where he guides the development of clinical platforms and precision health technologies. He also serves on the board of directors for Sana Biotechnology and contributes to advisory councils for the National Institutes of Health.

Awards and honors

Li's contributions have been recognized by numerous prestigious organizations. He was elected to the American Society for Clinical Investigation and the Association of American Physicians, honors reserved for leading physician-scientists. His research has been funded by major grants from the National Heart, Lung, and Blood Institute and the American Heart Association, which awarded him the Established Investigator Award. He has also delivered named lectureships at institutions including Stanford University School of Medicine and the Mayo Clinic.

Personal life

Dean Y. Li maintains a private personal life. He is known to be an advocate for mentorship in the biomedical sciences, frequently speaking on career development at events hosted by the American Association for the Advancement of Science. Residing in the San Francisco Bay Area, his interests outside of work include supporting initiatives that integrate technology and healthcare.

Category:American medical researchers Category:21st-century American physicians Category:American pharmaceutical executives